Global Leukapheresis Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|白血球血球分離的全球市場:2020年∼2027年 Global Leukapheresis Market - 2020-2027|
|出版日期: 2021年06月01日||內容資訊: 英文 180 Pages||
白細胞單採術是一種血液中白細胞數量減少的醫療程序，如果不及時治療，會導致癌症，例如血癌。全球白細胞單採市場的增長主要是由於白血病發病率增加、對 Leukopak 的需求增加以及更強大的給付政策。
The global leukapheresis market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Leukapheresis is a medical procedure to reduce the high count of white blood cells in the blood, which, when left untreated, can cause cancer, primarily blood cancers. When there is an increase in the count of leukocytes (white blood cells), blood density increases, and so does the viscosity. These leukocytes interfere with pulmonary and cerebral blood flow and compete with tissues for oxygen. In such cases, the body won't be able to fight infections. Reason Leukemia patients are more prone to die due to infections. It is also performed to obtain white blood cells for later transplant, such as to treat a steep decrease in WBC counts during cancer chemotherapy. Another use is part of a novel form of immunotherapy, called chimeric antigen receptor (CAR) T-cell therapy, to help fight leukemia, prostate cancer, and other forms of cancers. Some signs and symptoms of leukemia are fatigue and weakness, bleeding from gums, trauma, bruising, fever, weight loss etc. The market is expected to drive in the future due to the high prevalence rate of leukemia cases.
The global leukapheresis market growth is driven by the growing incidence of Leukemia, increasing demand for Leukopaks, and growing polices on reimbursement are among the key factors driving market growth.
Increased incidence of leukemia, is expected to drive the global leukapheresis market during the forecast period.
Globally, the prevalence rate of leukemia has increased majorly. According to the National Cancer Institute (NIH), in 2017, an estimated 434,982 people lived with leukemia in the United States. It also estimates, the number of new leukemia cases has increased at an average rate of 0.3% each year over the last ten years (from 2006 to 2015) and may reach 60,530 in 2020.
According to the Leukemia & Lymphoma Society, leukemia was the sixth-most-common cause of cancer deaths globally from 2010 to 2015.
An increasing number of blood donations and surging demand for leukopaks are expected to drive the global Leukapheresis market.
As per the Centers For Drug Control and Prevention (CDC), In the US alone, every day, approximately 44,000 units of blood are required in hospitals and emergency treatment facilities, and there are more than 13.2 million blood donors. About 21 million units of blood components are transfused every year. The requirement of leukocytes/WBCs increases with the rise in demand for leukopaks in clinical research for developing CAR-T therapy for leukemia.
High treatment costs of treatment are likely to hinder the global leukapheresis market growth
In the next few years, the high cost of leukapheresis procedures and the shortage of trained doctors. For instance, with equipment priced at $50,000 or more per machine, Leukapheresis disposables costing between $1,500 and $3,000 per patient is likely to hamper the market growth.
Based on the device type, the global leukapheresis market is segmented into leukapheresis devices (apheresis device, leukapheresis columns and cell separators, leukoreduction filters), leukapheresis disposables
Based on device type, the global leukapheresis devices market is segmented into apheresis devices, leukapheresis columns & cell separators, and leukoreduction filters. In 2017, the apheresis devices segment accounted for the largest share of the Leukapheresis Devices Market. The high share of this segment is attributed to the widespread adoption of apheresis devices for performing therapeutic leukapheresis procedures to treat leukemia and the development of leukopaks for clinical and preclinical research.
Based on treatment method, the global leukapheresis market is segmented into continuous apheresis and intermittent apheresis
There are two ways in which leukapheresis can be performed. One being continuos apheresis (CFC) and other being intermittent apheresis (IFC). Of these two, continuous apheresis is the most commonly used method.
Continuous Apheresis involves the removal of blood through one venipuncture site and the return of blood through a separate venipuncture site.
In IFC, apheresis is conducted in disrupted cycles, including full blood removal, separation of necessary cells, and reinfusion of the remaining components. For removal, separation and reinfusion, CFC is an uninterrupted or persistent flow. Large extracellular volume (ECV), haemodynamic fluctuations and longer duration of the procedure are the key drawbacks of IFC, which is why CFC is proliferating method.
Based on application, the global leukapheresis market is segmented into therapeutic applications and research applications
The research applications segment is expected to drive for the largest share of the global leukapheresis products market in 2018 due to the growing adoption of leukapheresis products in research activities propelled by increasing research activities being undertaken for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies.
Geographic Market Analysis
Asia -Pacific is the largest shareholder of the Leukapheresis market
The largest share of the market for leukapheresis products and leukopaks is projected to be in the Asia Pacific, followed by North America and Europe. The importance of APAC in this market is mainly due to the rise in the region's research in Regenerative Medicine, the increase in the number of clinical trials for CAR-T therapy, and leading pharmaceutical and biotech companies focused on cell therapy. Due to the advancement of healthcare infrastructure and services in the Asia Pacific, it is projected to see a high growth rate during the forecast period. Rising stem cell research will contribute positively to market growth in developing countries, such as India, Japan and China. The Japanese Ministry of Health, Labor, and Welfare approved the Regenerative Medicine Law in April 2013.
Global Leukapheresis Market Competitive Landscape
The global leukapheresis market has high competition among the key players like Asahi Kasei medical, Fresenius, Haemonetics Corporation, Terums BCT, STEMCELL Technologies, Macopharma, Hemacare, Allcells, Stemexpress, PPA research groups. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, Fresenius Kabi purchased the biosimilars company from Merck KGaA in September 2017. In February 2019, Fresenius Medical Care acquired NxStage, a US-based manufacturer of in-home dialysis systems, for $2 billion.
Asahi Kasei Medical
Company overview- It is a Japanese multinational chemical corporation. Chemicals and materials science are the primary products. It was founded in May 1931, using Nobeoka Ammonia Fiber Co., Ltd, a Nobeoka, Miyazaki-based producer of ammonia, nitric acid, and other chemicals, as paid-in capital. It now has its headquarters in Tokyo, with offices and services in Japan, as well as in China, Singapore, Thailand, the United States and Germany.
Products overview- The company deals with production of healthcare devices like blood transfusion, bioprocess products like leukocyte reduction filters, virus removal filters etc.
In 2019, Asahi Kasei acquired ViruSure. The company has completed its new spinning plant for Plannova filters.
The global leukapheresis market report would provide an access to an approx. 61 market data table, 50 figures and 300 pages.
LIST NOT EXHAUSTIVE